🤝 They’ve partnered with leading technology providers to enhance the system’s capabilities.
🔬 The Cell Q platform supports high throughput, scalable testing—up to 6,000 batches yearly—improving data quality and compliance.
📅 Cellares will showcase its advancements at the upcoming CAR-TCR Summit.
Introduction:
The article discusses the strategic initiatives taken by Cellares, a company specializing in automated quality control (QC) solutions for cell therapy manufacturing, to expand the capabilities of its Cell Q™ platform. The advancements are primarily aimed at enhancing automation and operational efficiency to meet the growing demands in commercial-scale cell therapy production.
- Cellares is collaborating with multiple strategic technology partners to enhance the features and functionalities of the Cell Q™ QC platform.
- The Cell Q platform is touted as a pioneering tool designed for high-throughput testing, capable of supporting automated QC release testing for up to 6,000 cell therapy batches annually.
- Key technology providers involved in the project include Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences, and AltemisLab, each contributing specific technological advancements.
- Cellares emphasizes that the Cell Q ensures compliance with good manufacturing practices (GMP), thus supporting easier regulatory approvals and reducing operational risks.
- The advancements in the Cell Q platform will be showcased at the 10th Annual CAR-TCR Summit, emphasizing the transition from traditional bottlenecks to improved automation in QC testing.
Conclusion:
The initiatives outlined by Cellares to expand the Cell Q platform indicate a significant step forward in the automation of QC processes within cell therapy manufacturing. This not only aims to enhance efficiency and scalability but also positions Cell Q as a critical tool in ensuring compliance with rigorous regulatory standards, ultimately benefiting both early-stage and commercial developers in the field.
